Loskog A

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.

Naseri S, Cordova MM, Wenthe J, ..., Loskog A, Ullenhag GJ

J. Cell. Mol. Med. 28 (7) e18162 [2024-04-00; online 2024-03-18]

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients.

Sarén T, Ramachandran M, Gammelgård G, ..., Enblad G, Essand M

Clin. Cancer Res. 29 (20) 4139-4152 [2023-10-13; online 2023-08-04]

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Wenthe J, Naseri S, Hellström AC, ..., Eriksson E, Loskog A

Cancer Gene Ther. 27 (12) 948-959 [2020-12-00; online 2020-05-01]

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients.

Schiza A, Irenaeus S, Ortiz-Nieto F, ..., Ullenhag GJ, Ahlström H

Sci Rep 9 (1) 18069 [2019-12-02; online 2019-12-02]

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.

Eriksson E, Milenova I, Wenthe J, ..., Alemany R, Loskog A

J. Immunol. 202 (3) 787-798 [2019-02-01; online 2019-01-07]

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.

Eriksson E, Moreno R, Milenova I, ..., Alemany R, Loskog A

Gene Ther. 24 (2) 92-103 [2017-02-00; online 2016-12-01]